Abstract

The five original objectives of this Group provide high quality comprehensive mathematical biology and computational support to CHAVI.
Aim 1 is to develop novel methods for analysis of neutralizing antibody data.
Aim 2 is to develop phylogenetic tools for defining sequence correlates of biological characteristics.
Aim 3 is to support the structural biology program of CHAVI, the CHAVI B cell immunology and the vaccine design discovery teams.
Aim 4 is to provide the CHAVI sequence database analysis and support for all components of CHAVI.
Aim 5 will provide CTL peptide design for the T cell program.
Aim 6 was added in year two, and Alan Perelson was brought into the program to lead a mathematical modeling component of the project, to model primary infection, the immune response to infection, and the impact of vaccines

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI067854-06
Application #
8105388
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2010-07-01
Project End
2012-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
6
Fiscal Year
2010
Total Cost
$2,090,071
Indirect Cost

  Institution

Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705

  Publications

Song, Hongshuo; Giorgi, Elena E; Ganusov, Vitaly V et al. (2018) Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nat Commun 9:1928
Boelen, Lies; Debebe, Bisrat; Silveira, Marcos et al. (2018) Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV, and HTLV-1. Sci Immunol 3:
Winawer, Melodie R; Griffin, Nicole G; Samanamud, Jorge et al. (2018) Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol 83:1133-1146
Pacheco, Beatriz; Alsahafi, Nirmin; Debbeche, Olfa et al. (2017) Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors. J Virol 91:
Fouda, Genevieve G; Eudailey, Joshua; Kunz, Erika L et al. (2017) Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization. Mucosal Immunol 10:228-237
Shen, Xiaoying; Bogers, Willy M; Yates, Nicole L et al. (2017) Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. J Virol 91:
Fischetti, Lucia; Zhong, Ziyun; Pinder, Christopher L et al. (2017) The synergistic effects of combining TLR ligand based adjuvants on the cytokine response are dependent upon p38/JNK signalling. Cytokine 99:287-296
Gelfman, Sahar; Wang, Quanli; McSweeney, K Melodi et al. (2017) Annotating pathogenic non-coding variants in genic regions. Nat Commun 8:236
Mori, Mari; Haskell, Gloria; Kazi, Zoheb et al. (2017) Sensitivity of whole exome sequencing in detecting infantile- and late-onset Pompe disease. Mol Genet Metab 122:189-197
Seaton, Kelly E; Vandergrift, Nathan A; Deal, Aaron W et al. (2017) Computational analysis of antibody dynamics identifies recent HIV-1 infection. JCI Insight 2:

Showing the most recent 10 out of 395 publications